In liver, ROS inhibit AKT phosphorylation, enabling nuclear FoxO1 to upregulate gluconeogenic (PEPCK, G6Pase) and lipogenic genes, exacerbating hyperglycemia and steatosis. Here, G6PC1 is linked to steatosis.